Registration Page

We are offering a variety of program dates and times in order to best meet your scheduling needs.

This initiative is designed to provide information and resources on HER2-+ breast cancer and is targeted to the unique educational needs of the nursing community. This program will summarize key information from the Adjuvant and Metastatic Herceptin clinical trials regarding the patient eligibility criteria, efficacy and safety data, and monitoring and management of Herceptin-associated toxicities.

Please Note: The same content will be presented at all programs; please enroll in the program which works best with your schedule.

Please note this is a promotional program and no CEUs will be offered.

» Nurse Dinner Programs

If you need assistance, please call our event specialists:


Telephone: (877) 282-4050

Fax: (888) 251-5650



Indications
Adjuvant indications
Herceptin is indicated for adjuvant treatment of HER2-overexpressing node-positive or node-negative (ER/PR-negative or with one high-risk feature) breast cancer:

  • As part of a treatment regimen containing doxorubicin, cyclophosphamide, and either paclitaxel or docetaxel
  • With docetaxel and carboplatin
  • As a single agent following multi-modality anthracycline-based therapy
Metastatic indications
Herceptin is indicated:
  • In combination with paclitaxel for the first line treatment of HER2 overexpressing metastatic breast cancer
  • As a single agent for treatment of HER2 overexpressing breast cancer in patients who have received one or more chemotherapy regimens for metastatic disease
Boxed WARNINGS and Additional Important Safety Information Herceptin administration can result in sub-clinical and clinical cardiac failure manifesting as congestive heart failure and decreased left ventricular ejection fraction. Serious infusion reactions and pulmonary toxicity have occurred; fatal infusion reactions have been reported. Exacerbation of chemotherapy-induced neutropenia has also occurred. The most common adverse reactions associated with Herceptin use were fever, nausea, vomiting, infusion reactions, diarrhea, infections, increased cough, headache, fatigue, dyspnea, rash, neutropenia, anemia, and myalgia.

Please click here for full prescribing information for Boxed WARNINGS and additional important safety information.